Showing 1–14 of 14 results for author: Bujkiewicz, S

Multi-indication evidence synthesis in oncology health technology assessment

Authors: Janharpreet Singh, Sumayya Anwer, Stephen Palmer, Pedro Saramago, Anne Thomas, Sofia Dias, Marta Soares, Sylwia Bujkiewicz

Abstract: Background: Cancer drugs receive licensing extensions to include additional indications as trial evidence on treatment effectiveness accumulates. We investigate how sharing information across indications can strengthen the inferences supporting Health Technology Assessment (HTA). Methods: We applied meta-analytic methods to randomised trial data on bevacizumab to share information across cancer in… ▽ More Background: Cancer drugs receive licensing extensions to include additional indications as trial evidence on treatment effectiveness accumulates. We investigate how sharing information across indications can strengthen the inferences supporting Health Technology Assessment (HTA). Methods: We applied meta-analytic methods to randomised trial data on bevacizumab to share information across cancer indications on the treatment effect on overall survival (OS) or progression-free survival (PFS), and on the surrogate relationship between effects on PFS and OS. Common or random parameters were used to facilitate sharing and the further flexibility of mixture models was explored. Results: OS treatment effects lacked precision when pooling data available at present-day within each indication, particularly for indications with few trials. There was no suggestion of heterogeneity across indications. Sharing information across indications provided more precise inferences on treatment effects, and on surrogacy parameters, with the strength of sharing depending on the model. When a surrogate relationship was used to predict OS effects, uncertainty was only reduced with sharing imposed on PFS effects in addition to surrogacy parameters. Corresponding analyses using the earlier, sparser evidence available for particular HTAs showed that sharing on both surrogacy and PFS effects did not notably reduce uncertainty in OS predictions. Limited heterogeneity across indications meant that the added flexibility of mixture models was unnecessary. Conclusions: Meta-analysis methods can be usefully applied to share information on treatment effectiveness across indications to increase the precision of target indication estimates in HTA. Sharing on surrogate relationships requires caution, as meaningful precision gains require larger bodies of evidence and clear support for surrogacy from other indications. △ Less

Submitted 21 November, 2023; originally announced November 2023.

Comments: 24 pages, 5 figures, 1 table

Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis

Authors: Chinyereugo M Umemneku-Chikere, Lorna Wheaton, Heather Poad, Devleena Ray, Ilse Cuevas Andrade, Sam Khan, Paul Tappenden, Keith R Abrams, Rhiannon K Owen, Sylwia Bujkiewicz

Abstract: Objective: We aimed to develop a meta-analytic model for evaluation of predictive biomarkers and targeted therapies, utilising data from digital sources when individual participant data (IPD) from randomised controlled trials (RCTs) are unavailable. Methods: A Bayesian network meta-regression model, combining aggregate data (AD) from RCTs and IPD, was developed for modelling time-to-event data t… ▽ More Objective: We aimed to develop a meta-analytic model for evaluation of predictive biomarkers and targeted therapies, utilising data from digital sources when individual participant data (IPD) from randomised controlled trials (RCTs) are unavailable. Methods: A Bayesian network meta-regression model, combining aggregate data (AD) from RCTs and IPD, was developed for modelling time-to-event data to evaluate predictive biomarkers. IPD were sourced from electronic health records, using target trial emulation approach, or digitised Kaplan-Meier curves. The model is illustrated using two examples; breast cancer with a hormone receptor biomarker, and metastatic colorectal cancer with the Kirsten Rat Sarcoma (KRAS) biomarker. Results: The model developed allowed for estimation of treatment effects in two subgroups of patients defined by their biomarker status. Effectiveness of taxane did not differ in hormone receptor positive and negative breast cancer patients. Epidermal growth factor receptor (EGFR) inhibitors were more effective than chemotherapy in KRAS wild type colorectal cancer patients but not in patients with KRAS mutant status. Use of IPD reduced uncertainty of the sub-group specific treatment effect estimates by up to 49%. Conclusion: Utilisation of IPD allowed for more detailed evaluation of predictive biomarkers and cancer therapies and improved precision of the estimates compared to use of AD alone. △ Less

Submitted 7 August, 2023; originally announced August 2023.

Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations

Authors: Lorna Wheaton, Dan Jackson, Sylwia Bujkiewicz

Abstract: During drug development, evidence can emerge to suggest a treatment is more effective in a specific patient subgroup. Whilst early trials may be conducted in biomarker-mixed populations, later trials are more likely to enrol biomarker-positive patients alone, thus leading to trials of the same treatment investigated in different populations. When conducting a meta-analysis, a conservative approach… ▽ More During drug development, evidence can emerge to suggest a treatment is more effective in a specific patient subgroup. Whilst early trials may be conducted in biomarker-mixed populations, later trials are more likely to enrol biomarker-positive patients alone, thus leading to trials of the same treatment investigated in different populations. When conducting a meta-analysis, a conservative approach would be to combine only trials conducted in the biomarker-positive subgroup. However, this discards potentially useful information on treatment effects in the biomarker-positive subgroup concealed within observed treatment effects in biomarker-mixed populations. We extend standard random-effects meta-analysis to combine treatment effects obtained from trials with different populations to estimate pooled treatment effects in a biomarker subgroup of interest. The model assumes a systematic difference in treatment effects between biomarker-positive and biomarker-negative subgroups, which is estimated from trials which report either or both treatment effects. The estimated systematic difference and proportion of biomarker-negative patients in biomarker-mixed studies are used to interpolate treatment effects in the biomarker-positive subgroup from observed treatment effects in the biomarker-mixed population. The developed methods are applied to an illustrative example in metastatic colorectal cancer and evaluated in a simulation study. In the example, the developed method resulted in improved precision of the pooled treatment effect estimate compared to standard random-effects meta-analysis of trials investigating only biomarker-positive patients. The simulation study confirmed that when the systematic difference in treatment effects between biomarker subgroups is not very large, the developed method can improve precision of estimation of pooled treatment effects while maintaining low bias. △ Less

Submitted 6 June, 2023; originally announced June 2023.

Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: Bayesian evidence synthesis with target trial emulation

Authors: Sylwia Bujkiewicz, Janharpreet Singh, Lorna Wheaton, David Jenkins, Reynaldo Martina, Kimme Hyrich, Keith R. Abrams

Abstract: Objective: We aim to utilise real world data in evidence synthesis to optimise an evidence base for the effectiveness of biologic therapies in rheumatoid arthritis in order to allow for evidence on first-line therapies to inform second-line effectiveness estimates. Study design and setting: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)… ▽ More Objective: We aim to utilise real world data in evidence synthesis to optimise an evidence base for the effectiveness of biologic therapies in rheumatoid arthritis in order to allow for evidence on first-line therapies to inform second-line effectiveness estimates. Study design and setting: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) to supplement RCT evidence obtained from the literature, by emulating target trials of treatment sequences to estimate treatment effects in each line of therapy. Treatment effects estimates from the target trials inform a bivariate network meta-analysis (NMA) of first and second-line treatments. Results: Summary data were obtained from 21 trials of biologic therapies including 2 for second-line treatment and results from six emulated target trials of both treatment lines. Bivariate NMA resulted in a decrease in uncertainty around the effectiveness estimates of the second-line therapies, when compared to the results of univariate NMA, and allowed for predictions of treatment effects not evaluated in second-line RCTs. Conclusion: Bivariate NMA provides effectiveness estimates for all treatments in first- and second-line, including predicted effects in second-line where these estimates did not exist in the data. This novel methodology may have further applications, for example for bridging networks of trials in children and adults. △ Less

Submitted 5 January, 2022; originally announced January 2022.

Using Bayesian Evidence Synthesis Methods to Incorporate Real World Evidence in Surrogate Endpoint Evaluation

Authors: Lorna Wheaton, Anastasios Papanikos, Anne Thomas, Sylwia Bujkiewicz

Abstract: Objective: Traditionally validation of surrogate endpoints has been carried out using RCT data. However, RCT data may be too limited to validate surrogate endpoints. In this paper, we sought to improve validation of surrogate endpoints with the inclusion of real world evidence (RWE). Study Design and Setting: We use data from comparative RWE (cRWE) and single arm RWE (sRWE), to supplement RCT ev… ▽ More Objective: Traditionally validation of surrogate endpoints has been carried out using RCT data. However, RCT data may be too limited to validate surrogate endpoints. In this paper, we sought to improve validation of surrogate endpoints with the inclusion of real world evidence (RWE). Study Design and Setting: We use data from comparative RWE (cRWE) and single arm RWE (sRWE), to supplement RCT evidence for evaluation of progression free survival (PFS) as a surrogate endpoint to overall survival (OS) in metastatic colorectal cancer (mCRC). Treatment effect estimates from RCTs, cRWE and matched sRWE, comparing anti-angiogenic treatments with chemotherapy, were used to inform surrogacy patterns and predictions of the treatment effect on OS from the treatment effect on PFS. Results: Seven RCTs, four cRWE studies and three matched sRWE studies were identified. The addition of RWE to RCTs reduced the uncertainty around the estimates of the parameters for the surrogate relationship. Addition of RWE to RCTs also improved the accuracy and precision of predictions of the treatment effect on OS obtained using data on the observed effect on PFS. Conclusion: The addition of RWE to RCT data improved the precision of the parameters describing the surrogate relationship between treatment effects on PFS and OS and the predicted clinical benefit. △ Less

Submitted 16 December, 2021; originally announced December 2021.

Comments: 13 pages, 2 figures

Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level a Bayesian approach and application to surrogate endpoint evaluation

Authors: Tasos Papanikos, John R Thompson, Keith R Abrams, Sylwia Bujkiewicz

Abstract: Bivariate meta-analysis provides a useful framework for combining information across related studies and has been utilised to combine evidence from clinical studies to evaluate treatment efficacy on two outcomes. It has also been used to investigate surrogacy patterns between treatment effects on the surrogate endpoint and the final outcome. Surrogate endpoints play an important role in drug devel… ▽ More Bivariate meta-analysis provides a useful framework for combining information across related studies and has been utilised to combine evidence from clinical studies to evaluate treatment efficacy on two outcomes. It has also been used to investigate surrogacy patterns between treatment effects on the surrogate endpoint and the final outcome. Surrogate endpoints play an important role in drug development when they can be used to measure treatment effect early compared to the final outcome and to predict clinical benefit or harm. The standard bivariate meta-analytic approach models the observed treatment effects on the surrogate and the final outcome outcomes jointly, at both the within-study and between-studies levels, using a bivariate normal distribution. For binomial data, a normal approximation on log odds ratio scale can be used. However, this method may lead to biased results when the proportions of events are close to one or zero, affecting the validation of surrogate endpoints. In this paper, we explore modelling the two outcomes on the original binomial scale. Firstly, we present a method that uses independent binomial likelihoods to model the within-study variability avoiding to approximate the observed treatment effects. However, the method ignores the within-study association. To overcome this issue, we propose a method using a bivariate copula with binomial marginals, which allows the model to account for the within-study association. We applied the methods to an illustrative example in chronic myeloid leukemia to investigate the surrogate relationship between complete cytogenetic response (CCyR) and event-free-survival (EFS). △ Less

Submitted 18 May, 2022; v1 submitted 4 April, 2020; originally announced April 2020.

Comments: 22 pages, 5 figures

The use of registry data to extrapolate overall survival results from randomised controlled trials

Authors: Reynaldo Martina, Keith Abrams, Sylwia Bujkiewicz, David Jenkins, Pascale Dequen, Michael Lees, Frank A. Corvino, Jessica Davies

Abstract: Background: Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in randomised controlled trials (RCTs). However, for regulatory and Health Technology Assessment (HTA) decision-making a longer time horizon is often required than is studied in RCTs. Therefore, extrapolation is required to estimate long-term treatment effect. Registry data can provide… ▽ More Background: Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in randomised controlled trials (RCTs). However, for regulatory and Health Technology Assessment (HTA) decision-making a longer time horizon is often required than is studied in RCTs. Therefore, extrapolation is required to estimate long-term treatment effect. Registry data can provide evidence to support extrapolation of treatment effects from RCTs, which are considered the main sources of evidence of effect for new drug applications. A number of methods are available to extrapolate survival data, such as Exponential, Weibull, Gompertz, log-logistic or log-normal parametric models. The different methods have varying functional forms and can result in different survival estimates. Methods: The aim of this paper was to use registry data to supplement the relatively short term RCT data to obtain long term estimates of effect. No formal hypotheses were tested. We explore the above parametric regression models as well as a nonparametric regression model based on local linear (parametric) regression. We also explore a Bayesian model constrained to the long term estimate of survival reported in literature, a Bayesian power prior approach on the variability observed from published literature, and a Bayesian Model Averaging (BMA) approach. The methods were applied to extrapolate overall survival of a RCT in metastatic melanoma. Results: The results showed that the BMA approach was able to fit the RCT data well, with the lowest variability of the area under the curve up to 72 months with or without the SEER Medicare registry. Conclusion: the BMA approach is a viable approach to extrapolate overall survival in the absence of long term data. △ Less

Submitted 24 October, 2019; originally announced November 2019.

Comments: 21 Pages, 7 named figures, 3 tables

A Bayesian hierarchical meta-analytic method for modelling surrogate relationships that vary across treatment classes using aggregate data

Authors: Tasos Papanikos, John Thompson, Keith Abrams, Nicolas Staedler, Oriana Ciani, Rod Taylor, Sylwia Bujkiewicz

Abstract: Surrogate endpoints play an important role in drug development when they can be used to measure treatment effect early compared to the final clinical outcome and to predict clinical benefit or harm. Such endpoints are assessed for their predictive value of clinical benefit by investigating the surrogate relationship between treatment effects on the surrogate and final outcomes using meta-analytic… ▽ More Surrogate endpoints play an important role in drug development when they can be used to measure treatment effect early compared to the final clinical outcome and to predict clinical benefit or harm. Such endpoints are assessed for their predictive value of clinical benefit by investigating the surrogate relationship between treatment effects on the surrogate and final outcomes using meta-analytic methods. When surrogate relationships vary across treatment classes, such validation may fail due to limited data within each treatment class. In this paper, two alternative Bayesian meta-analytic methods are introduced which allow for borrowing of information from other treatment classes when exploring the surrogacy in a particular class. The first approach extends a standard model for the evaluation of surrogate endpoints to a hierarchical meta-analysis model assuming full exchangeability of surrogate relationships across all the treatment classes, thus facilitating borrowing of information across the classes. The second method is able to relax this assumption by allowing for partial exchangeability of surrogate relationships across treatment classes to avoid excessive borrowing of information from distinctly different classes. We carried out a simulation study to assess the proposed methods in nine data scenarios and compared them with subgroup analysis using the standard model within each treatment class. We also applied the methods to an illustrative example in colorectal cancer which led to obtaining the parameters describing the surrogate relationships with higher precision. △ Less

Submitted 4 September, 2019; v1 submitted 17 May, 2019; originally announced May 2019.

Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer

Authors: Eleni G. Elia, Nicolas Städler, Oriana Ciani, Rod S. Taylor, Sylwia Bujkiewicz

Abstract: Progression free survival (PFS) and tumour response (TR) have been investigated as surrogate endpoints for overall survival (OS) in advanced colorectal cancer (aCRC), however their validity has been shown to be suboptimal. In recent years, meta-analytic methods allowing for use of multiple surrogate endpoints jointly have been proposed. The aim of this research was to assess if PFS and TR used joi… ▽ More Progression free survival (PFS) and tumour response (TR) have been investigated as surrogate endpoints for overall survival (OS) in advanced colorectal cancer (aCRC), however their validity has been shown to be suboptimal. In recent years, meta-analytic methods allowing for use of multiple surrogate endpoints jointly have been proposed. The aim of this research was to assess if PFS and TR used jointly as surrogate endpoints to OS improve their predictive value. Data were obtained from a systematic review of randomised controlled trials investigating effectiveness of different pharmacological therapies in aCRC: systemic chemotherapies, anti-epidermal growth factor receptor therapies, anti-angiogenic agents, other multi-targeted antifolate treatments and intra-hepatic arterial chemotherapy. Multivariate meta-analysis was used to model the association patterns between treatment effects on the surrogate endpoints (PFS, TR) and the final outcome (OS). Analysis of 33 trials which reported treatment effects on all three outcomes showed reasonably strong association between treatment effects on PFS and OS. A weak surrogate relationship was noted between the treatment effects on TR and OS. Modelling the two surrogate endpoints, TR and PFS, jointly as predictors of OS gave no marked improvement in neither surrogacy patterns nor the precision of predicted treatment effect in the cross-validation procedure. When investigating subgroups of therapy, only small improvement in precision of predicted treatment effects on the final outcome in studies investigating anti-angiogenic therapy was noted. Overall, the simultaneous modelling of two surrogate endpoints did not lead to improvement in association between treatment effects on surrogate and final endpoints in aCRC. △ Less

Submitted 9 September, 2018; originally announced September 2018.

Bivariate network meta-analysis for surrogate endpoint evaluation

Authors: Sylwia Bujkiewicz, Dan Jackson, John R Thompson, Rebecca Turner, Keith R Abrams, Ian R White

Abstract: Surrogate endpoints are very important in regulatory decision-making in healthcare, in particular if they can be measured early compared to the long-term final clinical outcome and act as good predictors of clinical benefit. Bivariate meta-analysis methods can be used to evaluate surrogate endpoints and to predict the treatment effect on the final outcome from the treatment effect measured on a su… ▽ More Surrogate endpoints are very important in regulatory decision-making in healthcare, in particular if they can be measured early compared to the long-term final clinical outcome and act as good predictors of clinical benefit. Bivariate meta-analysis methods can be used to evaluate surrogate endpoints and to predict the treatment effect on the final outcome from the treatment effect measured on a surrogate endpoint. However, candidate surrogate endpoints are often imperfect, and the level of association between the treatment effects on the surrogate and final outcomes may vary between treatments. This imposes a limitation on the pairwise methods which do not differentiate between the treatments. We develop bivariate network meta-analysis (bvNMA) methods which combine data on treatment effects on the surrogate and final outcomes, from trials investigating heterogeneous treatment contrasts. The bvNMA methods estimate the effects on both outcomes for all treatment contrasts individually in a single analysis. At the same time, they allow us to model the surrogacy patterns across multiple trials (different populations) within a treatment contrast and across treatment contrasts, thus enabling predictions of the treatment effect on the final outcome for a new study in a new population or investigating a new treatment. Modelling assumptions about the between-studies heterogeneity and the network consistency, and their impact on predictions, are investigated using simulated data and an illustrative example in advanced colorectal cancer. When the strength of the surrogate relationships varies across treatment contrasts, bvNMA has the advantage of identifying treatments for which surrogacy holds, thus leading to better predictions. △ Less

Submitted 24 July, 2018; originally announced July 2018.

Methods for the inclusion of real world evidence in network meta-analysis

Authors: David Jenkins, Humaira Hussein, Reynaldo Martina, Pascale Dequen-O'Byrne, Keith R Abrams, Sylwia Bujkiewicz

Abstract: Background: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. We investi… ▽ More Background: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. We investigate methods for the inclusion of RWE in NMA and its impact on the uncertainty around the effectiveness estimates. Methods: A range of methods for inclusion of RWE in evidence synthesis, including Bayesian hierarchical and power prior models, were investigated by applying them to an example in relapsing remitting multiple sclerosis. The effect of the inclusion of RWE was investigated by varying the degree of down weighting of this part of evidence by the use of a power prior. Results: Whilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding effect estimates in this example, this depended on the method of inclusion adopted for the RWE. Power prior NMA model resulted in stable effect estimates for fingolimod yet increasing the width of the credible intervals with increasing weight given to RWE data. The hierarchical NMA models were effective in allowing for heterogeneity between study designs; however, this also increased the level of uncertainty. Conclusion: The power prior approach for the inclusion of RWE in NMAs indicates that the degree to which RWE is taken into account can have a significant impact on the overall level of uncertainty. The hierarchical modelling approach further allowed for accommodating differences between study types. Consequently, further work investigating both empirical evidence for biases associated with individual RWE studies and methods of elicitation from experts on the extent of such biases is warranted. △ Less

Submitted 22 July, 2021; v1 submitted 17 May, 2018; originally announced May 2018.

Comments: 24 pages, 3 figures

Bayesian multi-parameter evidence synthesis to inform decision-making: a case study in hormone-refractory metastatic prostate cancer

Authors: Sze Huey Tan, Keith R Abrams, Sylwia Bujkiewicz

Abstract: In health technology assessment, decisions are based on complex cost-effectiveness models which, to be implemented, require numerous input parameters. When some of relevant estimates are not available the model may have to be simplified. Multi-parameter evidence synthesis allows to combine data from diverse sources of evidence resulting in obtaining estimates required in clinical decision-making t… ▽ More In health technology assessment, decisions are based on complex cost-effectiveness models which, to be implemented, require numerous input parameters. When some of relevant estimates are not available the model may have to be simplified. Multi-parameter evidence synthesis allows to combine data from diverse sources of evidence resulting in obtaining estimates required in clinical decision-making that otherwise may not be available. We demonstrate how bivariate meta-analysis (BVMA) can be used to predict unreported estimate of a treatment effect enabling implementation of multi-state Markov model, which otherwise needs to be simplified. To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer (mHRPC). BVMA was used to model jointly available data on treatment effects on overall survival (OS) and progression-free survival (PFS) to predict the unreported effect on PFS in a study evaluating docetaxel. Predicted treatment effect on PFS allowed implementation of a three-state Markov model comprising of stable disease, progressive disease and death states, whilst lack of the estimate restricted the model to two-state model (stable disease and death states). The two-state and three-state models were compared by calculating incremental cost-effectiveness ratios, which was much lower in the three-state model: £21966 per QALY gained compared to £30026 obtained from the two-state model. In contrast to the two-state model, the three-state model has the advantage of distinguishing patients who progressed from those who did not progress. The use of advanced meta-analytic technique helped to obtain relevant parameter estimate to populate a model which describes natural history more accurately, and at the same helped to prevent valuable clinical data from being discarded. △ Less

Submitted 31 May, 2017; originally announced May 2017.

A matrix-based method of moments for fitting multivariate network meta-analysis models with multiple outcomes and random inconsistency effects

Authors: Dan Jackson, Sylwia Bujkiewicz, Martin Law, Richard D Riley, Ian White

Abstract: Random-effects meta-analyses are very commonly used in medical statistics. Recent methodological developments include multivariate (multiple outcomes) and network (multiple treatments) meta-analysis. Here we provide a new model and corresponding estimation procedure for multivariate network meta-analysis, so that multiple outcomes and treatments can be included in a single analysis. Our new multiv… ▽ More Random-effects meta-analyses are very commonly used in medical statistics. Recent methodological developments include multivariate (multiple outcomes) and network (multiple treatments) meta-analysis. Here we provide a new model and corresponding estimation procedure for multivariate network meta-analysis, so that multiple outcomes and treatments can be included in a single analysis. Our new multivariate model is a direct extension of a univariate model for network meta-analysis that has recently been proposed. We allow two types of unknown variance parameters in our model, which represent between-study heterogeneity and inconsistency. Inconsistency arises when different forms of direct and indirect evidence are not in agreement, even having taken between-study heterogeneity into account. However the consistency assumption is often assumed in practice and so we also explain how to fit a reduced model which makes this assumption. Our estimation method extends several other commonly used methods for meta-analysis, including the method proposed by DerSimonian and Laird (1986). We investigate the use of our proposed methods in the context of a real example. △ Less

Submitted 25 May, 2017; originally announced May 2017.

Journal ref: Biometrics 2017

Creation of solitons and vortices by Bragg reflection of Bose-Einstein condensates in an optical lattice

Authors: R. G. Scott, A. M. Martin, T. M. Fromhold, S. Bujkiewicz, F. W. Sheard, M. Leadbeater

Abstract: We study the dynamics of Bose-Einstein condensates in an optical lattice and harmonic trap. The condensates are set in motion by displacing the trap and initially follow simple semiclassical paths, shaped by the lowest energy band. Above a critical displacement, the condensate undergoes Bragg reflection. For high atom densities, the first Bragg reflection generates a train of solitons and vortic… ▽ More We study the dynamics of Bose-Einstein condensates in an optical lattice and harmonic trap. The condensates are set in motion by displacing the trap and initially follow simple semiclassical paths, shaped by the lowest energy band. Above a critical displacement, the condensate undergoes Bragg reflection. For high atom densities, the first Bragg reflection generates a train of solitons and vortices, which destabilize the condensate and trigger explosive expansion. At lower densities, soliton and vortex formation requires multiple Bragg reflections, and damps the center-of-mass motion. △ Less

Submitted 12 July, 2002; v1 submitted 27 June, 2002; originally announced June 2002.

Comments: 5 pages including 5 figures (for higher resolution figures please email the authors)

Journal ref: Phys. Rev. Lett. 90, 110404 (2003).